{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:52:25Z","timestamp":1774536745886,"version":"3.50.1"},"reference-count":39,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Tumour volume percentage (TVP) is considered an important pathological parameter, particularly in prostate cancer, representing the ratio of tumour volume to the total gland, and it can be used to measure the quantity of malignancy. Previous reports have already demonstrated that an elevated tumour volume percentage is associated with unfavourable factors, including extraprostatic extension, positive surgical margins, and lymph node metastasis. The independent value of TVP, especially in high-risk prostate cancer treated by radical prostatectomy, remains an area of active research, despite established prognostic factors such as PSA, ISUP grade, and TNM stage. Materials and Methods: We retrospectively analyzed the records of 159 high-risk prostate cancer patients who underwent open or laparoscopic radical prostatectomy between January 2016 and January 2025 at the Clinic of Urology of Targu Mures. High-risk patients were defined as those with ISUP grade 4\u20135 or PSA &gt;20 ng\/mL or clinical stage \u2265T2c or stage cT3\u20134 and\/or lymph node metastasis. Tumour volume percentage was calculated from the final pathology result and was determined as the proportion of prostate cancer volume relative to the total prostate volume. Clinical and pathological features, including PSA, ISUP grade, TNM stage, surgical margin, and lymph node involvement, were reported. To assess TVP as an indicator of tumour aggressiveness, univariate and multivariate regression analyses were performed. A p-value &lt; 0.05 was considered statistically significant. Results: A total of 159 high-risk prostate cancer patients (100%), with a median age of 66 years, who underwent open or laparoscopic radical prostatectomy were included. The median tumour volume percentage was 7.6%, and the median prostate volume was 43.8 cc. On univariate analysis, patients with extraprostatic extension (p &lt; 0.001), positive surgical margins (p = 0.005), a higher ISUP grade (p &lt; 0.001), and lymph node metastasis (p = 0.006) exhibited higher TVP compared to their counterparts. A significant correlation was also observed between TVP and the number of positive biopsy cores (p &lt; 0.001), a higher PSA value (p = 0.005), and a younger age (p = 0.041). Conversely, no correlation was identified between TVP and perioperative factors such as hospital stay, surgery duration, ICU days, type of approach, or positive urine culture. Two regression models on multivariate analyses were performed with TVP as the dependent variable. In the continuous variable model (Adjusted R2 = 0.43, p &lt; 0.001), independent predictors of higher TVP were the number of positive biopsy cores (B = 0.54, p &lt; 0.001), the number of positive lymph nodes (B = 2.59, p &lt; 0.001), and surgical margin dimension (B = 1.19, p &lt; 0.001). Age, PSA, and perioperative variables showed no significant correlation with TVP on multivariate analysis. In the categorical regression model (Adjusted R2 = 0.438), statistical significance was confirmed (F-test, p &lt; 0.001). Independent predictors of increased tumour volume percentage included ISUP grade 5 in the effect-coded model (B = +6.60, 95% CI: 0.96\u201312.25, p = 0.022), and pathological TNM stage pT4 (B = +24.70, 95% CI: 17.69\u201331.70, p &lt; 0.001). ROC analysis showed limited-to-moderate discrimination for positive surgical margins (AUC = 0.655; 95% CI 0.565\u20130.744; p = 0.001) and stronger discrimination for pN1 (AUC = 0.793; 95% CI 0.650\u20130.936; p = 0.002). The Youden-derived cut-offs were 4.90% for positive surgical margins and 5.77% for lymph-node metastasis. Conclusions: Tumour volume percentage is significantly associated with several adverse pathological features in high-risk prostate cancer. Rather than a standalone biomarker, its association with adverse pathological features underscores its potential role in risk stratification models, and the incorporation into pathology reports and prognostic nomograms may improve clinical decision-making.<\/jats:p>","DOI":"10.3390\/cancers18071069","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:36:40Z","timestamp":1774532200000},"page":"1069","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathological Tumour Volume Percentage as a Quantitative Biomarker of Biological Aggressiveness in High-Risk Prostate Cancer"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8009-3482","authenticated-orcid":false,"given":"Lorand Tibor","family":"Reman","sequence":"first","affiliation":[{"name":"Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"},{"name":"Department of Urology, Targu Mures, Clinical Hospital, Piata Bernady Gyorgy, Nr. 6, 540072 Targu Mures, Romania"},{"name":"Institution Organizing University Doctoral Studies (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u0103lin","family":"Chibelean","sequence":"additional","affiliation":[{"name":"Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"},{"name":"Department of Urology, Targu Mures, Clinical Hospital, Piata Bernady Gyorgy, Nr. 6, 540072 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4279-673X","authenticated-orcid":false,"given":"Daniel","family":"Porav-Hodade","sequence":"additional","affiliation":[{"name":"Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"},{"name":"Department of Urology, Targu Mures, Clinical Hospital, Piata Bernady Gyorgy, Nr. 6, 540072 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1rp\u00e1d-Oliv\u00e9r","family":"Vida","sequence":"additional","affiliation":[{"name":"Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"},{"name":"Department of Urology, Targu Mures, Clinical Hospital, Piata Bernady Gyorgy, Nr. 6, 540072 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciprian Todea","family":"Moga","sequence":"additional","affiliation":[{"name":"Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"},{"name":"Department of Urology, Targu Mures, Clinical Hospital, Piata Bernady Gyorgy, Nr. 6, 540072 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica Maria","family":"Ghirca","sequence":"additional","affiliation":[{"name":"Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"},{"name":"Department of Urology, Targu Mures, Clinical Hospital, Piata Bernady Gyorgy, Nr. 6, 540072 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4778-380X","authenticated-orcid":false,"given":"Raul-Dumitru","family":"Gherasim","sequence":"additional","affiliation":[{"name":"Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"},{"name":"Department of Urology, Targu Mures, Clinical Hospital, Piata Bernady Gyorgy, Nr. 6, 540072 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rares-Florin","family":"Vascul","sequence":"additional","affiliation":[{"name":"Institution Organizing University Doctoral Studies (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya-Brigitta","family":"Katona","sequence":"additional","affiliation":[{"name":"Institution Organizing University Doctoral Studies (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"},{"name":"Department of Anaesthesiology and Intensive Care, County Emergency Clinic Hospital of Targu Mures, 540139 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szabolcs","family":"Andre","sequence":"additional","affiliation":[{"name":"Department of Urology, Targu Mures, Clinical Hospital, Piata Bernady Gyorgy, Nr. 6, 540072 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edva Anna","family":"Frunda","sequence":"additional","affiliation":[{"name":"Institution Organizing University Doctoral Studies (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya Katalin Ilona","family":"Martha","sequence":"additional","affiliation":[{"name":"Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania"},{"name":"Department of Urology, Targu Mures, Clinical Hospital, Piata Bernady Gyorgy, Nr. 6, 540072 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 Update on Prostate Cancer Epidemiology and Risk Factors\u2014A Systematic Review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wu, J., Jin, X., Li, J., Zhao, L., Zhao, C., Yu, N., Li, Y., Yan, J., Wang, J., and Yang, F. (2025). Development and validation of a prostate cancer risk prediction model for the elevated PSA population. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1599266"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/jamaoncol.2025.2304","article-title":"Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group","volume":"11","author":"Patel","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wang, J., Ying, L., and He, P. (2025). The influence of extraprostatic extension grade on the detection of pelvic lymph node metastasis in prostate cancer. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1663809"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.21873\/cdp.10443","article-title":"Preoperative Predictive Factors for Seminal Vesicle Invasion (pT3b) in Robotic-assisted Radical Prostatectomy","volume":"5","author":"Oshinomi","year":"2025","journal-title":"Cancer Diagn. Progn."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bju.16732","article-title":"Positive surgical margin and oncological outcomes after robot-assisted radical prostatectomy in different Cancer of the Prostate Risk Assessment risk groups","volume":"136","author":"Hagman","year":"2025","journal-title":"BJU Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2024.04.034","article-title":"Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer\u20142020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.eururo.2006.05.024","article-title":"Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience","volume":"51","author":"Hsu","year":"2007","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.12954\/PI.13018","article-title":"The role of radical prostatectomy in high-risk prostate cancer","volume":"1","author":"Chung","year":"2013","journal-title":"Prostate Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102626","DOI":"10.1016\/j.ctrv.2023.102626","article-title":"Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU)","volume":"120","author":"Sargos","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_15","first-page":"71.e9","article-title":"Comparison of oncologic outcomes following robot-assisted radical prostatectomy in high- and very high-risk prostate cancer based on the 2025 National Comprehensive Cancer Network risk stratification","volume":"44","author":"Ozawa","year":"2026","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.juro.2006.04.048","article-title":"Poorly Differentiated Prostate Cancer Treated With Radical Prostatectomy: Long-Term Outcome and Incidence of Pathological Downgrading","volume":"176","author":"Donohue","year":"2006","journal-title":"J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12957-025-03905-z","article-title":"Lesional volume in the prediction of clinically significant prostate cancer","volume":"23","author":"Brodie","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.euros.2022.12.002","article-title":"Prostate Cancer Tumor Volume and Genomic Risk","volume":"48","author":"Ramaswamy","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Peng, Y., Wei, C., Li, Y., Zhao, F., Liu, Y., Jiang, T., Chen, Z., Zheng, J., Fu, J., and Wang, P. (2025). Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings. BMC Urol., 25.","DOI":"10.1186\/s12894-025-01719-5"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1001\/jama.289.20.2695","article-title":"For The Polyp Prevention Trial Study Group Variation of Serum Prostate-Specific Antigen Levels: An Evaluation of Year-to-Year Fluctuations","volume":"289","author":"Eastham","year":"2003","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00268-017-4432-6","article-title":"Breast and Tumour Volume Measurements in Breast Cancer Patients Using 3-D Automated Breast Volume Scanner Images","volume":"42","author":"Lagendijk","year":"2018","journal-title":"World J. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4103\/UA.UA_17_17","article-title":"Pathological nature of renal tumors\u2014Does size matter?","volume":"9","author":"Kurban","year":"2017","journal-title":"Urol. Ann."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Dieckmann, K.-P., Isbarn, H., Grobelny, F., Dumlupinar, C., Utschig, J., W\u00fclfing, C., Pichlmeier, U., and Belge, G. (2022). Testicular Neoplasms: Primary Tumour Size Is Closely Interrelated with Histology, Clinical Staging, and Tumour Marker Expression Rates\u2014A Comprehensive Statistical Analysis. Cancers, 14.","DOI":"10.3390\/cancers14215447"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41585-022-00648-4","article-title":"Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway","volume":"20","author":"Barrett","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Baba, H., Sakamoto, S., Zhao, X., Yamada, Y., Rii, J., Fujimoto, A., Kanesaka, M., Takeuchi, N., Sazuka, T., and Imamura, Y. (2022). Tumor Location and a Tumor Volume over 2.8 cc Predict the Prognosis for Japanese Localized Prostate Cancer. Cancers, 14.","DOI":"10.3390\/cancers14235823"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41391-021-00468-4","article-title":"Is tumour volume an independent predictor of outcome after radical prostatectomy for high-risk prostate cancer?","volume":"26","author":"Raison","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1038\/s41598-022-09431-2","article-title":"The tumor volume after radical prostatectomy and its clinical impact on the prognosis of patients with localized prostate cancer","volume":"12","author":"Yuk","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pros.23486","article-title":"Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer","volume":"78","author":"Miki","year":"2018","journal-title":"Prostate"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2024.10.006","article-title":"Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection","volume":"87","author":"Touijer","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1007\/s00259-025-07255-6","article-title":"Long-term outcomes of PSMA PET\/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: A 5-year follow-up analysis","volume":"52","author":"Siepe","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0302-2838(02)00493-1","article-title":"Prognostic Significance of Tumor Volume after Radical Prostatectomy: A Multivariate Analysis of Pathological Prognostic Factors","volume":"43","author":"Salomon","year":"2003","journal-title":"Eur. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5534\/wjmh.2016.34.2.123","article-title":"The Effect of Tumor-Prostate Ratio on Biochemical Recurrence after Radical Prostatectomy","volume":"34","author":"Cho","year":"2016","journal-title":"World J. Mens. Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/PAT.0b013e3283420155","article-title":"Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup","volume":"43","author":"Hong","year":"2011","journal-title":"Pathology"},{"key":"ref_35","first-page":"445","article-title":"Can Tumour Volume Percentage in Radical Prostatectomy Predict Cancer Biochemical Recurrence? Determining a Cut-off Point and Composite Risk Factors Approach","volume":"13","author":"Alenezi","year":"2021","journal-title":"Res. Rep. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.eururo.2010.01.040","article-title":"Predictive Factors for Positive Surgical Margins and Their Locations After Robot-Assisted Laparoscopic Radical Prostatectomy","volume":"57","author":"Coelho","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-025-05680-8","article-title":"Multiparametric MRI lesion dimension as a significant predictor of positive surgical margins following laparoscopic radical prostatectomy for transitional zone prostate cancer","volume":"43","author":"Chen","year":"2025","journal-title":"World J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/01.ju.0000130481.04082.1a","article-title":"Is tumor volume an independent prognostic factor in clinically localized prostate cancer?","volume":"172","author":"Kikuchi","year":"2004","journal-title":"J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Fan, J., Xu, K., Jiang, Z., Gan, C., Song, H., Gao, G., Wang, G., Kang, Q., Luo, L., and Wang, Z. (2025). Role of 18F-PSMA-1007 PET\/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: A retrospective study. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13482-9"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/7\/1069\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:56:43Z","timestamp":1774533403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/7\/1069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cancers18071069"],"URL":"https:\/\/doi.org\/10.3390\/cancers18071069","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]}}}